Daiichi's sales rose & Astellas' sales fell

Japanese pharmaceutical companies are experiencing mixed results

Analysis of corporate sales and operating profit as of the end of March

Increased sales to Daiichi, Takeda, Ono, etc.

Among Japanese pharmaceutical companies that have entered the domestic market, 4 out of 7 subsidiaries with settlements in March expanded their sales.

 

Daiichi Sankyo Korea's sales reached 253.2 billion won, ranking first among Japanese pharmaceutical companies.

 

As a result of analyzing the performance for the 2022 business year (April 1, 2022, to March 31, 2023) of 7 pharmaceutical companies with settlements in March submitted to the Financial Supervisory Service on the 10th, the total sales amounted to KRW 1,115.4 billion, up from 11,557 in the previous year.

 

decreased by 3% compared to the billion won.

 

During the same period, operating profit fell 18% from 97.9 billion won to 80.2 billion won.

 

4 out of 7 companies succeeded in expanding their top line.

 

Four companies saw an increase in operating profit.

 

More than half improved performance, but the decline in performance at a particular company affected overall performance.

 

Daiichi Sankyo Korea posted 253.2 billion won in sales last year, up 3% from the previous year.

 

It surpassed Astellas Pharmaceuticals Korea and rose to No.

 

1 among Japanese pharmaceutical companies (including the December settlement).

 

Operating profit fell 16% to 22.1 billion won.

 

Lixiana·Sevikar sales made stable performance..

 

Since last year, it has been taking on a new challenge with the approval of the anti-cancer drug Enhertu.

 

There were also changes in the members of the organization, such as increasing the number of experts in anticancer drugs.

 

As a result, selling and administrative expenses increased and operating profit decreased.

 

Enhertu is a next-generation antibody-drug conjugate (ADC) that has proven efficacy not only in HER2-positive but also in HER2-low-expressing breast cancer for which there was no treatment.

 

In May, HER-2-positive breast cancer and stomach cancer passed the HIRA committee and benefits became possible.

 

If the benefit is applied within the year, it is expected to have a great impact on Daiichi Sankyo Korea's sales.

 

Takeda Pharmaceutical Korea and Astellas Korea Pharmaceutical, which cost about 200 billion won, obtained conflicting results last year.

 

Takeda Pharmaceutical Korea saw an increase in sales and a decrease in operating profit, while Astellas Pharmaceutical Korea saw a decrease in sales and an increase in operating profit.

 

Last year, Takeda Pharmaceutical Korea's sales were 249.6 billion won, up 8% from the previous year.

 

Operating profit fell 6% to 7.6 billion won.

 

Anticancer drugs such as Zejula, Alunbrig, and Ninlaro contributed to sales expansion with steady growth.

 

However, the decrease in operating profit was mainly due to the increase in the cost of sales.

 

Last year, Takeda Korea's cost of sales was 177 billion won, up 13 percent from 156.4 billion won the previous year.

 

Astellas Pharmaceutical Korea recorded 232.2 billion won in sales last year, down 6% from the previous year.

 

Representative products, such as Betmiga and Harnal, are continuously declining in sales.

 

Instead, the company is pinning its hopes on Xospata, a leukemia drug that succeeded in applying for reimbursement last year.

 

Saving on SG&A expenses, operating profit increased by 16% last year to KRW 17.6 billion.

 

Eisai's sales decreased by 34% from 212.9 billion won in 2021 to 140.5 billion won last year.

 

During the same period, operating profit also decreased by 77% to 5.2 billion won.

 

Sales of existing products such as Lenvima have declined, while new drugs such as Jyseleca have not yet generated significant sales in the market.

 

Eisai, which exceeded 200 billion won in annual sales for the first time in 2019, fell back to the 100 billion won level in three years.

 

Lecanemab is a promising new drug that will bring Eisai back.

 

Lecanemab, jointly developed by Biogen and Eisai, is a drug that can fundamentally treat Alzheimer's disease and is expected to exceed 1 trillion won in global sales by 2027.

 

Lecanemab, which received conditional approval from the FDA last year, was recently approved as an official drug, raising expectations for commercialization.

 

In particular, Eisai, not Biogen, is leading the commercialization of Lecanemab.

 

Eisai submitted an application for domestic approval of Lecanemab last month.

 

Santen Korea recorded 120.2 billion won and 16.9 billion won in sales and operating profit, up 10% and 6%, respectively.

 

Mitsubishi Tanabe Korea had the same sales as the previous year, but its operating profit increased by 7%.

 

Ono Pharma recorded sales of 50.1 billion won, up 23% last year thanks to the growth of the immuno-oncology drug Opdivo.